1 October
2024
PureTech Health plc
PureTech to Present at CHEST
2024 Annual Meeting
Three presentations inform
clinical, commercial and patient engagement strategies for LYT-100
for the treatment of idiopathic pulmonary fibrosis
(IPF)
Topline data from the Phase
2b ELEVATE IPF trial of LYT-100 expected by the end of
2024
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated
to changing the lives of patients with devastating diseases,
today announced its onsite presence at the CHEST 2024 Annual
Meeting in Boston, Massachusetts, from October 6-9. The Company
will deliver two oral presentations and one poster relating to
LYT-100 (deupirfenidone) for the treatment of idiopathic pulmonary
fibrosis (IPF) as well as the Company's research surrounding the
experiences of patients with IPF.
The data to be presented
have informed the clinical and
commercial strategies supporting LYT-100 as
well as advocacy and patient engagement work around the
management and treatment of people with IPF.
Topline results from the Phase 2b ELEVATE IPF trial are expected by
the end of 2024. A streamlined development program for LYT-100 is
planned using the same endpoints that have supported past IPF
product approvals. Pending positive clinical outcomes from
the Phase 2b trial and regulatory feedback, the
program is expected to advance into a Phase 3 trial. PureTech
believes the results of the Phase 2b trial, together with a
successful Phase 3 trial, could serve as the basis for registration
in the U.S. and other geographies.
Presentation Details
Presentation Title: Comparing
experiences at interstitial lung disease (ILD) centers and
community practices (CP) from the perspective of people with
idiopathic pulmonary fibrosis (IPF)
Session: Oral
presentation
Date
and Time: October 8, 2024 |
10:20-11:05am EDT
Presentation Title: Ongoing
burden of idiopathic pulmonary fibrosis (IPF) in the era of
antifibrotics
Session: Poster
presentation
Date
and Time: October 8, 2024 |
1:45-2:30pm EDT
Presentation Title: Bayesian
approach for ELEVATE IPF: Randomized, double-blind,
placebo-controlled trial to evaluate efficacy, safety, and dose
response of deupirfenidone (LYT-100) in IPF
Session: Oral
presentation
Date
and Time: October 8, 2024 |
1:45-2:30pm EDT
About Idiopathic Pulmonary Fibrosis
(IPF)
IPF is a rare, progressive and fatal
lung disease with a median survival of 2-5 years.[1] Pirfenidone is one of only two drugs
approved to treat IPF, and for those patients able to tolerate
treatment, it has been shown to improve survival by approximately
2.5 years compared to supportive care
alone.1 However, tolerability issues with both of
the standard-of-care drugs result in patients discontinuing
treatment or reducing their dose. This contributes to nearly three
out of every four people with IPF choosing to forego treatment with
these otherwise efficacious medicines.[2]
About LYT-100
(Deupirfenidone)
LYT-100 (deupirfenidone) is being
advanced for the treatment of conditions involving inflammation and
fibrosis, including IPF. It is a deuterated form of
pirfenidone that is designed to retain the beneficial pharmacology
and clinically-validated efficacy of pirfenidone with a highly
differentiated PK profile. LYT-100 has also
demonstrated favorable tolerability across multiple clinical
studies in more than 400 individuals.
Pirfenidone is one of the two
standard-of-care treatments approved for IPF, along with
nintedanib, both of which are efficacious but associated with
significant tolerability issues. These tolerability issues result
in treatment discontinuations and/or dose reductions below the
FDA-approved dose, thereby limiting the effectiveness of these
otherwise efficacious medicines. With
LYT-100, PureTech aims to deliver better outcomes for
patients by enabling individuals to maintain the same or higher
pirfenidone-equivalent doses for
longer. PureTech believes LYT-100 has the potential both
to supplant the current standard-of-care treatments and to serve a
larger market of patients who are unable to tolerate current
therapies. Topline data for the global
Phase 2 ELEVATE IPF trial are expected by the end of
2024.
About PureTech Health
PureTech is a clinical-stage
biotherapeutics company dedicated to giving life to new classes of
medicine to change the lives of patients with devastating diseases.
The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders that is being
advanced both internally and through its Founded Entities.
PureTech's R&D engine has resulted in the development of 29
therapeutics and therapeutic candidates, including three that have
been approved by the U.S. Food and Drug Administration. A number of
these programs are being advanced by PureTech or its Founded
Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit
www.puretechhealth.com
or connect with us on X (formerly Twitter)
@puretechh.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains
statements that are or may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including without limitation those related
to the LYT-100
development program and development plans, its potential benefits
to patients, the timing for results from the Phase 2b clinical
trial of LYT-100, the advancement of the
program into a Phase 3 trial, and our
future prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2023, filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
UK/EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US
Media
Nichole Bobbyn
+1 774 278 8273
nichole@tenbridgecommunications.com